Logo

BIVI

BioVie Inc.

BIVI

BioVie Inc. • NASDAQ
$1.50 ▲ 3.45% (+0.05)
Market Cap $11.31 M
52w High $31.50
52w Low $1.25
Dividend Yield 0%
P/E -0.25
Volume 61.07K
Outstanding Shares 7.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $5.227M ▲ $-5.131M ▼ 0% $-0.98 ▼ $-5.072M ▼
Q4-2025 $0 $3.606M ▲ $-3.489M ▼ 0% $0.98 ▲ $-3.427M ▼
Q3-2025 $0 $2.988M ▼ $-2.788M ▲ 0% $-1.5 ▲ $-2.931M ▲
Q2-2025 $0 $7.293M ▲ $-7.113M ▼ 0% $-4.6 ▲ $-7.235M ▼
Q1-2025 $0 $4.122M $-4.152M 0% $-7 $-4.065M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $24.978M ▲ $26.82M ▲ $1.899M ▼ $24.921M ▲
Q4-2025 $17.545M ▼ $21.562M ▼ $2.55M ▼ $19.012M ▼
Q3-2025 $23.152M ▼ $24.66M ▼ $2.842M ▲ $21.818M ▼
Q2-2025 $24.406M ▲ $25.694M ▲ $1.772M ▼ $23.923M ▲
Q1-2025 $20.023M $21.238M $7.171M $14.067M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-5.088M ▼ $-3.024M ▲ $0 $10.458M ▲ $7.434M ▲ $-3.024M ▲
Q4-2025 $-3.489M ▼ $-5.607M ▼ $0 $0 $-5.607M ▼ $-5.607M ▼
Q3-2025 $-2.788M ▲ $-1.254M ▲ $0 $0 ▼ $-1.254M ▼ $-1.254M ▲
Q2-2025 $-7.113M ▼ $-8.585M ▼ $0 $12.967M ▲ $4.382M ▲ $-8.585M ▼
Q1-2025 $-4.152M $-3.579M $0 $-240.937K $-3.82M $-3.579M

Five-Year Company Overview

Income Statement

Income Statement BioVie has no product revenue yet and has been running steady operating losses for several years, which is typical for a clinical‑stage biotech. All spending is essentially aimed at research, clinical trials, and overhead. Losses have narrowed somewhat more recently but remain meaningful relative to the company’s very small scale. The extremely large swings in per‑share loss mostly reflect repeated reverse stock splits rather than big changes in the underlying business. Overall, the income statement shows a company still firmly in the investment phase, with future profitability entirely dependent on successful drug approvals and commercialization, none of which are certain.

Balance Sheet

Balance Sheet The balance sheet is small and simple. Assets are modest and largely made up of cash, with only limited tangible resources beyond that. Debt has been used sparingly, which reduces financial strain from interest but also underscores how reliant the company is on equity funding. Shareholders’ equity remains positive but thin, reflecting cumulative losses over time. The multiple reverse splits in recent years indicate pressure on the share price and a capital structure that has likely seen meaningful dilution. Financially, this is a lean, high‑risk balance sheet that depends on continued access to capital markets or partnerships.

Cash Flow

Cash Flow BioVie consistently uses cash rather than generating it. Operating cash flow has been negative every year, driven by R&D and clinical spending without offsetting revenue. Capital expenditures are minimal, which means most cash burn is going directly into trials and operations rather than buildings or equipment. Free cash flow is therefore materially negative, and the business remains dependent on external financing—equity raises, possible debt, or upfront payments from partners—to fund its pipeline. The company’s future flexibility will hinge on how quickly it spends its cash relative to clinical milestones and funding events.

Competitive Edge

Competitive Edge BioVie is trying to compete in very challenging but high‑value disease areas: Alzheimer’s, Parkinson’s, and severe liver complications. Its main Alzheimer’s and Parkinson’s drug candidate uses a different mechanism focused on inflammation and insulin resistance, which helps it stand out from many amyloid‑focused rivals. In liver disease, its terlipressin infusion could be among the first drug options for a condition with few treatments. Strong patent coverage and special regulatory designations support its competitive position. However, as a small company, it faces intense competition from much larger pharma players, will likely need strong partners to commercialize, and remains highly exposed to any clinical or regulatory setbacks.

Innovation and R&D

Innovation and R&D The company’s value is centered on its R&D pipeline. Its lead brain drug has shown encouraging signals in both Alzheimer’s and Parkinson’s, but the Alzheimer’s Phase 3 study was undermined by trial‑quality issues, forcing a do‑over with a new once‑daily version. That adds time and uncertainty but also a chance to design a cleaner, more convincing trial. In Parkinson’s, early results in combination therapy were promising, with a larger study planned to test it on its own. The liver drug candidate showed meaningful benefit early enough that its trial was stopped and moved toward a Phase 3 design, contingent on securing a partner. BioVie is also exploring broader uses, such as long COVID neurological symptoms and healthy aging, suggesting platform potential—but all of this is still experimental and subject to high failure risk.

Summary

BioVie is a classic high‑risk, high‑uncertainty clinical‑stage biotech: no revenue, ongoing losses, modest cash resources, and heavy dependence on external funding. Its appeal rests on a focused set of innovative drug candidates that target large unmet medical needs with differentiated scientific approaches and decent early data, especially in Parkinson’s and liver disease. The Alzheimer’s program has both intriguing efficacy signals and real credibility challenges after the flawed Phase 3, making the repeat trial a pivotal moment for the company. The balance sheet and cash flows underline that there is little margin for prolonged delays or major disappointments. Overall, the story is about whether the company can convert promising science and a protective patent and regulatory position into successful late‑stage trials, partnerships, and eventually a sustainable commercial business amid significant scientific, regulatory, and financing risks.

NEWS

November 19, 2025 · 8:00 AM UTC

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Read more

October 24, 2025 · 8:20 AM UTC

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Read more

September 26, 2025 · 8:00 AM UTC

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Read more